期刊文献+

早期慢性肾脏病患者肺动脉压变化与心脏结构功能的相关性 被引量:1

Relationship between pulmonary arterial pressure changes in early-stage chronic kidney disease with cardiac structure and function
下载PDF
导出
摘要 目的探讨早期慢性肾脏病(CKD)肺动脉压(PAP)变化及其与心脏结构功能的相关性。方法将315例早期cKD患者和51名健康对照者PAP水平进行比较分析,探讨其与血浆脑钠肽(BNP)及左心室质量指数(LVMI)等心脏结构功能指标的相关性。结果①与对照组比较,早期CKD组PAP明显升高[(31.87±8.39)mmHg比(29.43±3.71)mmHg,P〈o.01];肺动脉高压(PHT)发生率12.06%;PHT在CKD1期已经出现,随肾功能恶化愈加严重。CKD2期始,InBNP和LVMI等心脏指标显著增高(P〈0.05)。LVMI和InBNP均是影响PAP的独立危险因素。结论早期CKD已出现PHT,PHT随肾功能恶化而增高,并与心脏结构功能变化密切相关。 Objective To explore the pulmonary arterial pressure(PAP) level in patients with early-stage chronic kidney disease(CKD) and its relationship to indexes of cardiac structure and func- tion. Methods 315 cases of early-stage CKD and 51 healthy controls were enrolled. The PAP level in each group was measured, and its correlation with indexes of cardiac structure and function such as LVMI,BNP was analyzed. Results (1)PAP level in early-stage CKD group was significantly higher than in control group [-(31.87 ± 8.39) vs (29. 43 ± 3.71) mmHg,P〈0. 011.12. 06% patients in early- stage CKD group were accompanied with pulmonary hypertension(PHT). PHT was observed in stage 1 of CKD, and deteriorated with progression of kidney injury; (2)Compared with control group, lnB- NP, LVMI and other cardiac indexes in early-stage CKD group were increased from stage 2 of CKD (P〈0.05). LVMI and lnBNP were both independent risk factors of PAP. Conclusions Pulmonary hy- pertension occurs in early-stage CKD. PAP level keeps increasing with progression of renal injury. PAP is related to indexes of cardiac structure and function.
出处 《临床肾脏病杂志》 2012年第4期165-167,共3页 Journal Of Clinical Nephrology
关键词 肾脏疾病 高血压 肺动脉 超声心动描记术 Nephrology Hypertension, pulmonary Echocardiography
  • 相关文献

参考文献11

  • 1Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest, 20(/3, 123: 1577- 1582.
  • 2Amin M, Fawzy A, Hamid MA, et al. Pulmonary Hypertension in patients with chronic renal failure. Chest, 2003,124: 2093-2097.
  • 3Berger M, Haimowitz A, Van Tosh P, et al. Quantitative assess- ment of pulmonary hypertension in patients with tricuspid regur- gitation using continuous wave Doppler ultrasound. J Am Coll Cardiol, 1985,6 : 359-365.
  • 4Meouillan BM, Picard MH, Leavitt M, et al. Clinical correlates and reference intervals for pulmonary artery systolic pressure a- mong eehoeardiographieally normal subjeets. Circulation, 2001, 104 : 2797-2802.
  • 5Havlucu Y,Kursat S, Ekmekci C, et al. Pulmonary hypertension in patients with chronic renal failure. Respiration,2007,74.503- 510.
  • 6杨青梅,鲍晓荣,张清,杜国伟,王昱,沈玛丽,王宏儒,汪丽珍,叶薇.慢性肾脏病肺动脉压变化及其相关因素分析[J].中国中西医结合肾病杂志,2011,12(8):702-705. 被引量:6
  • 7左志通,陈宝华,王旭,刘小铭,凌春华,张彩娣,邹新中,史建平.血浆B型利尿钠肽与慢性阻塞性肺疾病患者肺动脉压力相关性研究[J].实用医学杂志,2010,26(5):781-783. 被引量:17
  • 8Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical signif- icance of brain natriuretic peptide in primary pulmonary hyper- tension. J Am Coil Cardiol, 2004,43 : 764-770.
  • 9Cargill RI, Lipworth BJ. Acute effects of ANP and BNP on hy- poxie pulmonary vasoconstriction in humans. Br J Clin Pharma- col, 1995,40 : 585-590.
  • 10杨青梅,鲍晓荣.慢性肾脏病患者血浆同型半胱氨酸水平与左心室肥大的关系[J].临床肾脏病杂志,2010(7):308-310. 被引量:6

二级参考文献42

共引文献32

同被引文献14

  • 1Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data[J]. Lancet, 2005, 365(9945): 217-223.
  • 2Chobanian AV, Bakris GL, Black HR, et al. Seventh report of theJoint national committee on prevention, detection, evaluation, and treatment of high blood pressure[J]. Hypertension, 2003, 289(19): 1206-1252.
  • 3Esler M. The sympathetic system and hypertension[J]. Am 1 Hypertens , 2000, 13(6): 99S-105S.
  • 4Krum H, Schlaich M, Whitbourn R, et al. Catheter-based re- nal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study[J]. Lancet, 2009, 373(4): 1275-1281.
  • 5Investigators Symplicity HTN-1. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressurereduction out to 24 months. Hypertensionj I}, 2011,57: 911-917.
  • 6Grassi G, Cattaneo BM, Seravalle G, et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension[J]. Hypertension, 1998, 31(1): 68-72.
  • 7Esler MD, Krum H, Schlaich MR, et al. Sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled triale]]. Circulation, 2012, 126(25): 2976-2982.
  • 8Stephen G, Worthley, Costas P, et al. Safety and efficacy of a multi electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial[J]. European HeartJournal, 2013,34(74): 2132-2140.
  • 9GewirtzJR, BisognanoJD. Catheter-based renal sympathetic denervation, a targeted approach to resistant hypertension[J]. CardiolJ, 2011, 18(1): 97-102.
  • 10Mahfoud F, Cremers B, lankerJ, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension[J]. Hypertension August, 2012, 60(2): 419-424.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部